Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its …
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its …
The investigational triple agonist matched semaglutide on average glucose reduction and delivered roughly twice the percentage weight loss …
The interim Phase 1b dataset included eight efficacy-evaluable patients at cutoff, with post-cutoff confirmation lifting the reported rate …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, …
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions …
The RMAT-designated GABAergic interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy demonstrated sustained seizure control in updated …
Shionogi’s ensitrelvir becomes the only approved oral option for preventing COVID-19 following known exposure, filling a gap left …
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
BioMarin Pharmaceutical has announced positive pivotal Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, the most …
Already a subscriber? Log in